Cumberland sets ifetroban DMD heart-disease NDA plan after Apotex deal closes
The company reported Q3 2026 results, a $100 million strategic transaction close, and mixed next steps for ifetroban in two rare-disease programs.
SEC filing
3 stories
The company reported Q3 2026 results, a $100 million strategic transaction close, and mixed next steps for ifetroban in two rare-disease programs.
SEC filing
The company said it will submit a New Drug Application after a fall pre-NDA meeting with the FDA, using Phase 2 and natural history data rather than a new Phase 3 trial.
SEC filing
The company said the ASSIST-SSc trial results support the drug's safety and tolerability in the rare disease population.
SEC filing